Preventive treatment with atorvastatin ameliorates endothelial dysfunction of small pulmonary arteries in monocrotaline-induced pulmonary hypertensive rats

References

• Humbert M, Morrell NW, Archer SL et al. Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol 2004;43:13S–24S.
   Google Scholar
• Runo JR, Loyd JE. Primary pulmonary hypertension. Lancet 2003;361:1533–1544.
   PubMed Web of Science ®Google Scholar
• Guignabert C, Dorfmuller P. Pathology and pathobiology of pulmonary hypertension. Semin Respir Crit Care Med 2013;34(5):551–559.
   PubMed Web of Science ®Google Scholar
• McLaughin VV, Hoeper MM. Pulmonary arterial hypertension: the race for the most effective treatment. Am J Respir Crit Care Med 2005;171:1199–1201.
   PubMed Web of Science ®Google Scholar
• Chen D, Zhou D, Qian J et al. Atorvastatin prevents dehydromonocrotaline-induced pulmonary hypertension in beagles. Exp Lung Res 2012;38:333–343.
   PubMed Web of Science ®Google Scholar
• Koh KK. Effects of statins on vascular wall: vasomotor function, inflammation, and plaque stability. Cardiovasc Res 2000;47:648–657.
   PubMed Web of Science ®Google Scholar
• Maron DJ, Fazio S, Linton MF. Current perspectives on statins. Circulation 2000;101:207–213.
   PubMed Web of Science ®Google Scholar
• Satoh M, Takahashi Y, Tabuchi T et al. Cellular and molecular mechanisms of statins: an update on pleiotropic effects. Clin Sci (Lond) 2015;129(2):93–105.
   PubMed Web of Science ®Google Scholar
• Lin ZH, Xie L, Wu K, Wang HJ, Xu CS. Effects of fluvastatin on structure and function of resistant vessels in spontaneously hypertensive rats. Acta Pharmacologica Sinica 1999;20:855–860.
   Web of Science ®Google Scholar
• Xie L, Ouyang Q, Zhao H, et al. Effect of benazepril and fluvastatin on L-type calcium channel α1C expression in vascular smooth muscle cells from spontaneously hypertensive rats. Chin J Hypertension 2008;16:1100–1104.
   Google Scholar
• Ouyang QF, Han Y, Lin ZH, et al. Fluvastatin upregulates the α1C subunit of CaV1.2 channel expression in vascular smooth muscle cells via RhoA and ERK/p38 MAPK pathways. Dis Markers 2014;237067.
   Google Scholar
• Xie L, Lin P, Xie H, Xu C. Effects of atorvastatin and losartan on monocrotaline-induced pulmonary artery remodeling in rats. Clin Exp Hypertens 2010;32:547–554.
   PubMed Web of Science ®Google Scholar
• Guerard P, Rakotoniaina Z, Goirand F et al. The HMG-CoA reductase inhibitor, pravastatin, prevents the development of monocrotaline-induced pulmonary hypertension in the rat through reduction of endothelial cell apoptosis and overexpression of eNOS. Naunyn Schmiedebergs Arch Pharmacol 2006;373(6):401–414.
   PubMed Web of Science ®Google Scholar
• Rakotoniaina Z, Guerard P, Lirussi F et al. The protective effect of HMG-CoA reductase inhibitors against monocrotaline-induced pulmonary hypertension in the rat might not be a class effect: comparison of pravastatin and atorvastatin. Naunyn Schmiedebergs Arch Pharmacol 2006;374:195–206.
   PubMed Web of Science ®Google Scholar
• Ozturk EI, Uma S. Effects of atorvastatin and L-Arginine treatments on electrical field stimulation-mediated relaxations in pulmonary arterial rings of monocrataline-induced pulmonary hypertensive rats. J Cardiovasc Pharmacal 2010;5(56):498–505.
   Web of Science ®Google Scholar
• Luo L, Lin T, Zheng S et al. Adipose-derived stem cells attenuate pulmonary arterial hypertension and ameliorate pulmonary arterial remodeling in monocrotaline-induced pulmonary hypertensive rats. Clin Exp Hypertens 2015;37(3):241–248.
   PubMed Web of Science ®Google Scholar
• Liang M, Li H, Zheng S et al. Comparison of early and delayed transplantation of adipose tissue-derived mesenchymal stem cells on pulmonary arterial function in monocrotaline induced pulmonary arterial hypertensive rats. Eur Heart J 2015;17(supplement F):F4–F12.
   Web of Science ®Google Scholar
• Lin P, Xie X, Xie L et al. Pulmonary arteriolar remodeling is prior to the increase in pulmonary arterial pressure in rats. Chin J Hypertens 2007;15(10):839–843.
   Google Scholar
• Khan I, Oriowo MA, Chandrasekhar B, Kadavil EA. Atenuated noradrenaline-induced contraction of pulmonary arteries from rats treated with monocrotaline: role of Rho Kinase. J Vasc Res 2005;42:433–440.
   PubMed Web of Science ®Google Scholar
• Altiere RJ, Olson JW, Gillespie MN. Altered pulmonary vascular smooth muscle responsiveness in monocrotaline-induced pulmonary hypertension. J Pharmacol Exp Ther1986;236:390–395.
   PubMed Web of Science ®Google Scholar
• Liang M, Xie L, Li H, et al. Effects of early intervention of adipose-derived mesenchymal stem cells on function of pulmonary arterioles in rats with pulmonary arterial hypertension induced by monocrotaline. Chinese Journal of Pathophysiology 2013;29(10):1729–1735.
   Google Scholar
• Liang M, Xie L, Li H, et al. Effects of delayed intervention of adipose-derived mesenchymal stem cells on function of small pulmonary arterioles in rats with pulmonary arterial hypertension induced by monocrotaline. Chin J Hypertens 2013;21(9):831–837.
   Google Scholar
• Maruyama J, Maruyama K. Impaired nitric oxide-dependent responses and their recovery in hypertensive pulmonary arteries of rats. Am J Physiol 1994; 266 (6 Pt 2): H2476–H2488.
   PubMedGoogle Scholar
• Taraseviciene-Stewart L, Scerbavicius R, Choe KH et al. Simvastatin causes endothelial cell apoptosis and attenuates severe pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 2006;291:L668–L676.
   PubMed Web of Science ®Google Scholar
• Nishimura T, Faul JL, Berry GJ et al. Simvastatin attenuates smooth muscle neointimal proliferation and pulmonary hypertension in rats. Am J Respir Crit Care Med 2002;166:1403–1408.
   PubMed Web of Science ®Google Scholar
• Mason RP, Walter MF, Day CA, Jacob RF. Intermolecular differences of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors contribute to distinct pharmacologic and pleiotropic actions. Am J Cardiol 2005;96:11F–23F.
   PubMed Web of Science ®Google Scholar
• Taneva E, Borucki K, Wiens L et al. Early effects on endothelial function of atorvastatin 40 mg twice daily and its withdrawal. Am J Cardiol 2006;97:1002–1006.
   PubMed Web of Science ®Google Scholar